for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

44.19USD

Change

0.24(+0.55%)

Volume

3,661,248

Today's Range

44.16

 - 

44.71

52 Week Range

33.36

 - 

51.86

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
43.95
Open
44.29
Volume
3,661,248
3M AVG Volume
681.37
Today's High
44.71
Today's Low
44.16
52 Week High
51.86
52 Week Low
33.36
Shares Out (MIL)
5,606.69
Market Cap (MIL)
246,414.00
Forward P/E
10.70
Dividend (Yield %)
3.55

Next Event

Pfizer Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)

Latest Developments

More

CDC Statement On ACIP Booster Recommendations

Everest Medicines Announces Approval Of Investigational New Drug Application By China NMPA For SPR206

U.S. CDC Says 212,564,346 Individuals Have Received At Least One Dose Of Covid-19 Vaccine As Of Sept 23

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'amelio

Chief Financial Officer, Executive Vice President - Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Lidia Fonseca

Executive Vice President, Chief Technology Officer and Digital Officer

Key Stats

2.61 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

80.5K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

4.106
Price To Earnings (TTM)
20.08
Price To Sales (TTM)
4.44
Price To Book (MRQ)
3.51
Price To Cash Flow (TTM)
14.23
Total Debt To Equity (MRQ)
56.03
LT Debt To Equity (MRQ)
50.48
Return on Investment (TTM)
8.93
Return on Equity (TTM)
7.16

Latest News

Latest News

Pfizer in talks over full license for COVID-19 vaccine in Singapore

Pfizer Inc is in discussions with Singapore's Health Sciences Authority regarding obtaining a full license application for its COVID-19 vaccine, the company said in response to a query from Reuters.

Sinovac's COVID shot highly effective against serious illness- Malaysia study

Sinovac's COVID-19 vaccine is highly effective against serious illness, although rival shots from Pfizer/BioNTech and AstraZeneca showed better protection rates, a large real world study from Malaysia showed.

U.S. CDC director breaks with panel, backs COVID-19 boosters for high-risk workers

The U.S. Centers for Disease Control and Prevention (CDC) on Friday backed a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older, some adults with underlying medical conditions and some adults in high-risk working and institutional settings...

BRIEF-CDC Statement On ACIP Booster Recommendations

* CDC SAYS CDC DIRECTOR ENDORSED ACIP RECOMMENDATION FOR BOOSTER SHOT OF PFIZER-BIONTECH COVID-19 VACCINE IN CERTAIN POPULATIONS

Factbox-Latest on the worldwide spread of the coronavirus

A U.S. CDC advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions that put them at risk of severe disease.

U.S. CDC advisers recommend COVID-19 vaccine boosters for 65 and older, high risk

A U.S. Centers for Disease Control and Prevention advisory panel on Thursday recommended a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older and some adults with underlying medical conditions.

EU drugs regulator to decide on Pfizer vaccine booster in early October

The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review.

EU drugs regulator says to decide on Pfizer vaccine booster in early October

The European Medicines Agency (EMA) will likely decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course.

Exclusive - EU regulator to decide on Pfizer booster at the start of October - source

The European Medicines Agency (EMA) expects to decide in early October on the possible use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine, a source with direct knowledge of the matter told Reuters.

U.S. FDA clears Pfizer COVID-19 booster for older and at-risk Americans

The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc and BioNTech COVID-19 vaccine for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.

BRIEF-FDA Says Authorizes Booster Dose Of Pfizer-Biontech Covid-19 Vaccine For Certain Populations

* FDA SAYS AUTHORIZES BOOSTER DOSE OF PFIZER-BIONTECH COVID-19 VACCINE FOR CERTAIN POPULATIONS

Brazil regulator says adolescent death unrelated to Pfizer shot

The death of a 16-year-old who had a first dose of the Pfizer/BioNTech vaccine against COVID-19 was due to a prior blood clot condition not related to the vaccine, Brazil's health regulator Anvisa said on Wednesday.

Brazil health regulator says adolescent's death not related to Pfizer vaccine

Brazil's health regulator Anvisa said on Wednesday that the death of a 16-year-old who got a first dose of the Pfizer/BioNTech vaccine against COVID-19 earlier this month was not related to the vaccine.

U.S. FDA to authorize third dose of Pfizer COVID-19 vaccine for older Americans - Bloomberg

The U.S. Food and Drug Administration will authorize a booster dose of the Pfizer Inc and BioNTech COVID-19 vaccine for those aged 65 and older and some high-risk Americans, a Bloomberg News reporter said in a tweet https://twitter.com/LauraLitvan/status/1440797321126563842...

U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday

A U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc and partner BioNTech SE's COVID-19 vaccine on Thursday, an agency official said at a public meeting of the panel on Wednesday.

U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday

U.S. Centers for Disease Control and Prevention advisory panel could vote on the use of a third shot of Pfizer Inc and partner BioNTech SE's COVID-19 vaccine on Thursday, an agency official said while kicking off the two-day panel discussion on Wednesday.

BRIEF-Pfizer CEO Albert Bourla Says Decision To Provide Boosters Should Be Based On Science – CNBC Interview

* PFIZER CEO ALBERT BOURLA SAYS DECISION TO PROVIDE BOOSTERS SHOULD BE BASED ON SCIENCE – CNBC INTERVIEW Further company coverage:

UK and South Korea agree COVID-19 vaccine swap deal

Britain and South Korea have agreed to swap over 1 million COVID-19 vaccine doses with each other, with the UK sending a first batch of Pfizer shots in the coming weeks and Korea returning the same volume by the end of the year.

U.S. to donate an additional 500 million COVID-19 vaccines

The United States plans to donate an additional 500 million COVID-19 vaccines made by Pfizer Inc and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.

CORRECTED-UPDATE 1-U.S. to donate an additional 500 mln COVID-19 vaccines

The United States plans to donate an additional 500 million COVID-19 vaccines made by Pfizer Inc and BioNTech SE to nations around the world, lifting the total the country is sharing to more than 1 billion doses, according to a source familiar with the plans.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up